NEW YORK, NY, UNITED STATES, February 9, 2026 /EINPresswire.com/ — With years of experience in the pharmaceutical and life science sectors, CD Bioparticles has ...

A phase 1 study to evaluate the safety and tolerability of the antibody–drug conjugate (ADC) MesoC2 (PF-08052666) in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2025 ...